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The “Final Voyage”
of the Endeavor Stent*
Michael A. Kutcher, MD
Winston-Salem, North Carolina
The “final” 5-year outcomes of combined trials with the
Endeavor zotarolimus-eluting stent (E-ZES) by Kandzari
et al. (1), published in this issue of JACC: Cardiovascular
Interventions, might be considered a companion to the
Kirtane et al. (2) publication in the issue last month of
JACC: Cardiovascular Interventions, which reported on the
“final” 5-year follow-up of the ENDEAVOR IV (A Ran-
domized, Controlled Trial of the Medtronic Endeavor
Drug [ABT-578] Eluting Coronary Stent System Versus
the Taxus Paclitaxel-Eluting Coronary Stent System in De
Novo Native Coronary Artery Lesions) study. Both papers
represent an opportunity to place the long-term clinical
results of the Endeavor stent in perspective for the
here-and-now.
See page 504
But before plowing into the data and the implications of
these 2 studies, let us digress with a bit of history. The
percutaneous coronary intervention device industry, over the
years, has come up with some colorful names to highlight
and sell their products. The term “Endeavor” (American
English spelling) for the Medtronic second-generation ZES
ranks among one of the more intriguing device names that
has a basis in history. The sailing ship of Captain James
Cook on his first voyage of discovery in the South Seas
(1768 to 1771) was named the “HMS Endeavour” (British
English spelling). Over 200 years later and of a vastly
different travel destination, the Command Module of the
Apollo 15 moon mission was also named “Endeavour.” And
most recently, we can remember the striking images last
year of the retired Space Shuttle “Endeavour” riding piggy
back on a jumbo 747 airliner on its “final” voyage across the
United States and then towed through the streets of Los
*Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From Interventional Cardiology, Wake Forest School of Medicine, Medical Center
oulevard, Winston-Salem, North Carolina. Dr. Kutcher reports his institutioneceives Interventional Cardiology Fellowship grant support from the Abbott Fund,
dministered by Rockefeller Philanthropy Advisers.Angeles to a resting place at the California Science Center.
So, in a sense, with these reports on the “final” 5-year
follow-ups of the Endeavor stent, we might consider this
the “final voyage” of this interesting stent design.
The E-ZES stent program was born after the unbridled
enthusiastic use of first-generation drug-eluting stents
(DES) in the early 2000s was tempered by disturbing
reports of late stent thrombosis (3). Even though a meta-
analysis of randomized multicenter trials and registry data
demonstrated reasonable safety and efficacy of first-
generation DES compared with bare-metal stents (BMS)
(4), there continued to be major issues of cost-effectiveness,
late stent thrombosis, and the lack of a robust mortality
benefit with DES in more complex coronary lesions. Po-
tential problems in the first-generation DES, such as thick
stent struts, inflammation-inducing release polymers, and
the effectiveness of different anti-proliferative agents, set the
stage for improved second-generation concepts. The
E-ZES consists of a cobalt-based alloy stent with a phos-
phorylcholine polymer and a dose concentration of 10
g/mm stent length of zotarolimus, a sirolimus-like anti-
proliferative agent (5). It was speculated that the biocom-
patibility of the phosphorylcholine polymer would lead to
more gentle anti-proliferation and better endothelization of
the stent without the potential of inflammatory reactions
and exposure of stent struts to late stent thrombosis.
The E-ZES system was then assessed in various trials
comparing it with BMS, paclitaxel-eluting stents (PES),
and sirolimus-eluting stents (SES). The major multicenter
trials consisted of ENDEAVOR I (First-in-human study of
the Endeavor ABT-578-eluting phosphorylcholine-
encapsulated stent system in de novo native coronary artery
lesions) (E-ZES first in man) (5), ENDEAVOR II (Ran-
domized Controlled Trial to Evaluate the Safety and
Efficacy of the Medtronic AVE ABT-578 Eluting Driver
Coronary Stent in De Novo Native Coronary Artery Le-
sions) (E-ZES vs. BMS) (6), ENDEAVOR III (A Ran-
domized Controlled Trial of the Medtronic Endeavor Drug
[ABT-578] Eluting Coronary Stent System Versus the
Cypher Sirolumus-Eluting Coronary Stent System in De
Novo Native Coronary Artery Lesions) (E-ZES vs. SES)
(7), and ENDEAVOR IV (E-ZES vs. PES) (8). These 4
trials, at endpoints of 9 months to 1 year, consistently found
that E-ZES had greater surrogates of late lumen loss (LLL)
and angiographic restenosis compared with either SES or
PES. However, for the short-term these did not seem to
translate into deleterious separate or composite endpoints
for E-ZES.
Nevertheless, extended long-term outcomes with the
variety of DES in clinical practice is an important practice to
assure safety and effectiveness for the patient, particularly in
light of the potential for adverse signals of late and very late
stent thrombosis (VLST). The papers by Kirtane et al. (2)






J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 5 , 2 0 1 3
M A Y 2 0 1 3 : 5 1 3 – 5
Kutcher
Editorial Comment
514the sponsor, Medtronic (Minneapolis, Minnesota), and the
dedicated clinical investigators to submit the ENDEAVOR
trials to extended and structured 5-year clinical follow-up.
Last month in JACC: Cardiovascular Interventions, Kir-
tane et al. (2) reported on the “final” 5-year follow-up of the
ENDEAVOR IV randomized trial that compared E-ZES
with PES. This 5-year cumulative and landmark analysis of
clinical outcomes was performed in 722 (93.4%) E-ZES
patients and 718 (92.6%) PES patients. Overall rates of
target lesion revascularization (TLR) and target vessel
failure were similar. The incidence of cardiac death or
myocardial infarction (MI) was lower with E-ZES com-
pared with PES (6.4% vs. 9.1%, p  0.048), primarily
riven by a lower rate of MI (2.6% vs. 6%, p  0.002).
verall definite/probable stent thrombosis rates were simi-
ar between stents (1.3% vs. 2%, p  0.42). But rates of
VLST in E-ZES compared with PES (0.4% vs. 1.8%, p 
0.012) and late MI events (1.3% vs. 3.5%, p  0.008) were
significantly lower with E-ZES. The authors concluded
that E-ZES had durable long-term safety and efficacy
compared with PES. There were no late signals of adverse
events with E-ZES. The authors properly acknowledged
that the subsets of significantly reduced VLST and late MI
with E-ZES should be hypothesis-generating, given the
limited statistical power of the trial.
As an interesting sequel, the paper by Kandzari et al. (1) also
reports on a “final” 5-year clinical follow-up of the ENDEAVOR
clinical trial program, which consisted of 5 trials: ENDEAVOR I
(100 patients); ENDEAVOR II (1,194 patients); ENDEAVOR
III (436 patients); ENDEAVOR IV (1,548 patients); and an
ENDEAVOR II Continued Access Registry (9) (296 patients).
The authors intended to assess whether the higher short-term
incidence of LLL and angiographic restenosis translated to late
adverse clinical events in the combined ENDEAVOR trials. The
study cohort consisted of a total of 3,616 percutaneous coronary
intervention patients, of which 2,132 received E-ZES, 888 re-
ceived first-generation DES (775 PES, 113 SES), and 596
received BMS. The authors found that, when E-ZES was
compared with a parallel cohort of patients treated with first-
generation DES and BMS, 5-year rates of cardiac death/MI
(5.8% vs. 8.8% DES, p  0.003, vs. 8.4% BMS, p  0.02) and
ajor adverse cardiac events (16.1% vs. 20.6% DES, p 0.009,
s. 24.6% BMS, p 0.001) were significantly lower with E-ZES.
There were similar TLR rates when E-ZES was compared with
overall DES (7.4% vs. 8.1%, p  0.63). The TLR in E-ZES
compared with BMS was significantly lower (7.4% vs. 16.3%, p
0.001). The most striking finding was that, despite higher E-ZES
TLR in the first year compared with DES, the rates of cardiac
death/MI, TLR, and definite/probable stent thrombosis were
significantly lower with E-ZES in the 5-year time frame. The
authors concluded that rates of clinical restenosis and safety events,
including stent thrombosis beyond the first year of revasculariza-
tion remain stable with E-ZES, leading to significant differences
compared with first-generation DES. Again, because there areissues with the limited statistical power of these combined trials,
the results of these subset analyses should be considered
hypothesis-generating and not clear-cut mandates for safety or
efficacy.
The shortcomings of the E-ZES system rest in the
nondurable rapid release polymer, resulting in completed
elution of the active zotarolimus agent within 10 days (5).
As a result, the perceived Achilles heel of the E-ZES has
always been the increased LLL compared with other first-
generation and second-generation DES platforms. By con-
trast, the heightened re-endothelialization and incorpora-
tion of the E-ZES in the coronary lumen has been touted as
a potentially “safer” stent by reducing the risk of late stent
thrombosis and VLST. In essence, the E-ZES can be
considered intermediate between BMS and other limus-like
DES systems.
Regardless, in the current world, the E-ZES stent archi-
tecture has now been eclipsed by the Resolute zotarolimus-
eluting stent (R-ZES) system. The R-ZES polymer is a
mixture of a hydrophilic biocompatible component that
faces the endoluminal surface and a hydrophobic compo-
nent that is attached to a cobalt alloy stent surface and serves
as a drug reservoir. This results in a sustained release of
zotarolimus, one-half of the load over 10 to 14 days, and the
remainder more gradually over 8 to 10 weeks (10). The
clinical results of the R-ZES have been found to be
comparable to contemporary everolimus-eluting stents in an
“all-comers” trial (11).
Is the E-ZES a safer stent? The data from these 2 5-year
follow-ups would indicate long-term safety compared with
first-generation DES. But this is not definitive, due to the
limited statistical power of both of these analyses. We do
know for sure that E-ZES is not harmful in the long run.
But we should keep in mind that these studies were in
simple de novo coronary lesions. Is the E-ZES a superior
stent compared with SES or PES? Absolute superiority is
hard to prove—so the answer is no. But, one could conclude
that the E-ZES stent might be somewhat better than
first-generation DES, particularly in long-term clinical
outcomes. Is there a role for E-ZES as a work horse stent in
our current practice? Due to the march of time and even
newer DES platforms, the answer again is no. If a
zotarolimus-elution is preferable, the current choice would
be R-ZES in view of the improved elution dynamics and
newer underlying stent architecture. Thus, in final perspec-
tive, the Endeavor stent was an interesting transition from
first-generation to second-generation stents but one whose
time has now passed.
These “final” 5-year reports on the long-term outcomes of
the ENDEAVOR trials closes another chapter or “voyage” on
the meticulous conduct of these and other large-scale multi-
center randomized trials assessing various DES platforms and
elution schemes. Although the ENDEAVOR trials dealt with
older comparative stent designs that are not often used in
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515current clinical practice, the priority for publication and
dialogue of these 2 papers are justified by the importance of
the concept of a 5-year follow-up. There is a benefit to an
extended follow-up of randomized DES patients to assure
that there are no late-late deleterious signals that could
result in harm. This commitment to long-term follow-up
also helps to develop hypothesis-generating principles of
improved polymer compatibility and elution dynamics to
guide the next generations of DES, such as total bioabsorb-
able stents and unidirectional abluminal drug-elution stent
platforms. So, in the end, the long “final voyage” of the
Endeavor stent and the long-term information gained was
well worth the journey.
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